Study S001352

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05136287
Acronym: SEVERAL
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 140
Start: 2022-02-01
Primary completion: 2023-11-15
Lead sponsor: Jose Seijas Amigo
Conditions: Weight Loss; Diabetes Mellitus, Type 2; Quality of Life; Safety Issues
Interventions: DRUG:GLP-1 receptor agonist
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Weight loss [11 months]

Linked records (9)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001354	Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study). Seijas-Amigo J, Clinical therapeutics	2026	Nonrandomized study	PMID 42103575 DOI	cites ClinicalTrials.gov:NCT05136287; registry reference DERIVED:42103575
R0004840	Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study. Seijas-Amigo J, Diabetes & metabolic syndrome	2025	Randomized trial	PMID 41129847 DOI	cites ClinicalTrials.gov:NCT05136287; registry reference DERIVED:41129847
R0012932	Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study. Seijas-Amigo J, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria	2022	Randomized trial	PMID 36520578	registry reference BACKGROUND:36520578
R0023399	Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine	2021	Randomized trial	PMID 33567185 DOI	registry reference BACKGROUND:33567185
R0018537	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Gerstein HC, Lancet (London, England)	2019	Randomized trial	PMID 31189511 DOI	registry reference BACKGROUND:31189511
R0014565	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Pratley RE, The lancet. Diabetes & endocrinology	2018	Randomized trial	PMID 29397376 DOI	registry reference BACKGROUND:29397376
R0026028	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, The New England journal of medicine	2017	Nonrandomized study	PMID 28249135 DOI	registry reference BACKGROUND:28249135
R0022060	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27295427 DOI	registry reference BACKGROUND:27295427
R0013512	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Verspohl EJ, Pharmacology & therapeutics	2009	Preclinical	PMID 19545590 DOI	registry reference BACKGROUND:19545590